Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ExpreS2ion Biotechnologies has signed a research license agreement with University of Oxford to provide its Drosophila Schneider-2 cell-based technology platform - ExpreS2 for protein production.
Subscribe to our email newsletter
The platform, which is stable and non-lytic protein expression, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford.
The solution will also be used by various research teams to meet complex and difficult-to-make proteins.
ExpreS2ion Biotechnologies CEO Charlotte Dyring said ExpreS2ion is happy that the Jenner Institute has taken a Research License for protein expression.
”The ExpreS2 platform has shown to provide a way forward to projects with a need for a robust and fully scalable protein production platform, such as certain challenging recombinant subunit vaccine projects,” Dyring added.